Table 1 Characteristics of ART naive adults initiating ART in Uganda and Zimbabwe and surviving the first year of Therapy by main randomisation arm
| Â | Baseline characteristics at | |
|---|---|---|
|  |  randomisation and week 48 | |
Randomisation in main DART trial | LCM | CDM |
Total participants | 1478 | 1482 |
Sex | Â | Â |
Female | 970(66%) | 952(64%) |
WHO stage | Â | Â |
2 | 331(22%) | 291(20%) |
3 | 827(56%) | 844(57%) |
4 | 320(22%) | 345(23%) |
BMI | Â | Â |
<20 | 489(33%) | 515(35%) |
20-27 | 846(58%) | 831(56%) |
>27 | 130(9%) | 127(9%) |
CD4 cells/ μL |  |  |
Median (IQR) | 84(33-138) | 86(31-140) |
Age(years) at ART initiation | Â | Â |
Median (IQR) | 37(32-42) | 36(32-42) |
18-35 | 589(40%) | 593(40%) |
35-50 | 792(54%) | 796(54%) |
>50 | 97(6%) | 93(6%) |
Initial ART regimen | Â | Â |
Tenofovir (TDF) | 1075(73%) | 1087(73%) |
Nevirapine (NVP) | 260(18%) | 251(17%) |
Abacavir (ABC) | 143(10%) | 142(10%) |
Follow up at 48 weeks | Â | Â |
STI/CT randomisation | Â | Â |
Not randomised | 1061(72%) | 1082(73%) |
Randomised to STI | 209(14%) | 203(14%) |
Randomised to CT | 208(14%) | 197(13%) |
CD4 cells/ μL at week 48 |  |  |
Median (IQR) | 201(139-283) | 200(141-280) |
Weight at week 48 | Â | Â |
Median(IQR) | 63(57-71) | 63(56-71) |